Oncology – Gynecologic | Links Medicus Content Curation & Alerts in Medicine

Classifying adnexal lesion appearance as classic or nonclassic has high sensitivity and specificity for diagnosing malignancy in women at average risk for ovarian cancer. @BaranLab @drantil7 @kpatellippmann @katematuren @ayakamaya @hanna_zrad @LizSadowski https://t.co/6NphOIycMe pic.twitter.com/99DyWIHXwU

— Radiology (@radiology_rsna) March 28, 2022

Position Paper: Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer.

26 May, 2022 | 10:42h | UTC

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies – ESMO Open

Phase 1/2 RCT: Safety and efficacy of the mTOR inhibitor, Vistusertib, combined With Anastrozole in patients with hormone receptor−positive recurrent or metastatic endometrial cancer.

26 May, 2022 | 10:30h | UTC

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

Commentary on Twitter

Endocrine therapy is used in clinical practice in the management of relapsed or advanced HR + endometrial cancer. Anastrozole + vistusertib demonstrated clinically significant improvement with manageable adverse events, encouraging further research https://t.co/hHDtloSdNs #GynCSM

— JAMA Oncology (@JAMAOnc) May 12, 2022

Review: Outcomes of Enhanced Recovery after Surgery (ERAS) in gynecologic oncology.

6 May, 2022 | 10:22h | UTC

Outcomes of Enhanced Recovery after Surgery (ERAS) in Gynecologic Oncology: A Review – Current Oncology

Review: Advances in radiation oncology for the treatment of cervical cancer.

6 May, 2022 | 10:20h | UTC

Advances in Radiation Oncology for the Treatment of Cervical Cancer – Current Oncology

RCT: Topical imiquimod versus surgery for vulvar intraepithelial neoplasia.

3 May, 2022 | 10:30h | UTC

Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial – The Lancet (link to abstract – $ for full-text)

RCT: Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma.

20 Apr, 2022 | 09:09h | UTC

Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Advanced testing for human papillomavirus infection improves prognostic evaluation in cervical cancer.

18 Apr, 2022 | 09:33h | UTC

Human Papillomavirus Infection Determines Prognosis in Cervical Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)

Editorial: Testing for High-Risk Human Papillomavirus in Lower Genital Tract Tumors: If Knowledge Does Not Translate to an Action That Helps Patients—Why Do It? – Journal of Clinical Oncology

Commentary: Study Confirms Favorable Prognosis for HPV-Positive Cervical Cancer— RNA sequencing identified more HPV+ tumors, showed 43% mortality disparity for HPV- tumors – MedPage Today (free registration required)

RCT: Rucaparib vs. standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation.

6 Apr, 2022 | 09:45h | UTC

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: ARIEL4 Trial: Rucaparib vs Chemotherapy in Patients With Relapsed Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations – The ASCO Post

Commentary on Twitter

In ARIEL4 phase III trial, pts with BRCA1/2-mut ovarian cancer who received ≥2 chemo regimens received rucaparib or chemo. In the ITT, mPFS was 7.4 mo vs 5.7 mo (HR 0.67, 95% CI 0.52–0.86; P = 0.0017). Three treatment-related deaths occurred w rucaparib https://t.co/G7j7djp6kV

— NatureRevClinOncol (@NatRevClinOncol) March 22, 2022

Cohort Study: Association of lower extremity lymphedema with physical functioning and activities of daily living among older survivors of colorectal, endometrial, and ovarian cancer.

28 Mar, 2022 | 08:39h | UTC

Association of Lower Extremity Lymphedema With Physical Functioning and Activities of Daily Living Among Older Survivors of Colorectal, Endometrial, and Ovarian Cancer – JAMA Network Open

Commentaries:

Older female cancer survivors face challenges with physical activity due to chronic lower extremity lymphedema – News Medical

Lower-Extremity Lymphedema Common in Older, Female Cancer Survivors – HealthDay

Commentary on Twitter

Cohort study found nearly 1/3 of older female survivors of #ColorectalCancer, #EndometrialCancer, or #OvarianCancer have lower-extremity lymphedema (LEL), which is associated with worse physical function and needing assistance with ADLs. https://t.co/806Tt88TuV

— JAMA Network Open (@JAMANetworkOpen) March 9, 2022